CD4 and neoplasm: We observed an increase in CD4+ tumor-infiltrating T-cells (TILs) in the MDA-MB-231 xenografts treated with MB/OVs complexes with or without pembrolizumab adjuvant treatment compared to mice injected with unprotected OVs (IT or IV) or IV with control MBs (Figure 5).